基于库马林的PTP1B的菌抑制:一种潜在的新陈代谢调节策略
Emadeldin M Kamel1, Doaa A Abdelrheem1, Faris F Aba Alkhayl2
1Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
Journal of molecular recognition : JMR
|July 3, 2025
概括
来自Ammi majus的氨酸Bergapten和Imperatorin显示出强大的抑制蛋白氨酸酸酶1B (PTP1B),这是一个关键的代谢调节剂. 这些化合物显示出作为治疗2型糖尿病和肥胖症的全抑制剂的有前途潜力.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 计算化学的计算化学
背景情况:
- 蛋白氨酸酸酶1B (PTP1B) 是代谢调节中的关键酶,使其成为2型糖尿病和肥胖症的重要治疗点.
- 自然化合物越来越多地被探索它们在代谢障碍中的治疗潜力.
研究的目的:
- 评估从Ammi majus中分离的四种氨酸 (Bergapten, Imperatorin, Xanthotoxol, Isopimpinellin) 的PTP1B抑制活性.
- 通过in silico和in vitro方法研究这些库马林的结合机制和类似药物的特性.
主要方法:
- 包括分子对接,分子动力学 (MD) 模拟,主要能源景观 (PEL) 分析和MM/PBSA计算在内的in silico方法.
- 在体外PTP1B抑制试验和酶动力学研究.
- 用于药物相似性预测的ADMET分析.
主要成果:
- 伯加和帝国林表现出强大的结合亲和力和与PTP1B的稳定相互作用,由对接,MD和PEL分析证实.
- 在体外试验中,Bergapten (IC50 = 6.64 μM) 和Imperatorin (IC50 = 9.44 μM) 显示出强大的PTP1B抑制,与乌尔索酸相比.
- 酶动力学揭示了Bergapten和Imperatorin的一种非竞争性,全性抑制机制.
结论:
- 伯加和 Imperatorin 被确定为有效的 PTP1B 的全抑制剂.
- 这些氨酸具有有利的类似药物的特性和强大的抑制活性,表明它们对代谢障碍的治疗潜力.
- 需要进一步的临床前研究来探索Bergapten和Imperatorin在细胞和动物模型中的疗效.
更多相关视频
相关概念视频
Regulation of Metabolism
9.9K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.9K
Allosteric Proteins-ATCase
5.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.9K
Allosteric Regulation
59.1K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
59.1K
Feedback Inhibition
54.6K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
54.6K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Enzyme Inhibition
79.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.7K


